Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Celgene Corp (NQ: CELG)
116.89 USD  UNCHANGED
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Celgene Corp
 
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals
June 18, 2013
Editor Note: For more information about this release, please scroll to bottom Read More
from PR Newswire
Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
June 17, 2013
from Business Wire News Releases
Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease
June 14, 2013
from Business Wire News Releases
Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
June 13, 2013
from Business Wire News Releases
Celgene Announces Additional $3.0 Billion Share Repurchase Program
June 12, 2013
from Business Wire News Releases
Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)
June 12, 2013
from Business Wire News Releases
La Administración de Drogas y Alimentos de los Estados Unidos aprueba REVLIMID® ®(lenalidomida) para el tratamiento de pacientes con linfoma de células del manto en recidiva o refractario
June 07, 2013
from Business Wire Spanish
Celgene Corporation to Webcast at Upcoming Investor Conference
June 06, 2013
from Business Wire News Releases
U.S. Food and Drug Administration Approves REVLIMID® (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
June 05, 2013
from Business Wire News Releases
Los análisis del ensayo MPACT que evalúa la terapia en combinación con ABRAXANE® para el tratamiento del cáncer de páncreas avanzado se presentaron en ASCO 2013
June 04, 2013
from Business Wire Spanish
Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at ASCO 2013
June 03, 2013
from Business Wire News Releases
Celgene Announces Launch of “Innovation Impact” Awards to Recognize Excellence in Creative Patient, Caregiver or Healthcare Provider Programs
May 31, 2013
from Business Wire News Releases
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
May 31, 2013
from Business Wire News Releases
Celgene anuncia que la FDA de Estados Unidos ha concedido la revisión prioritaria para la solicitud complementaria de nuevo fármaco para ABRAXANE® en el cáncer pancreático avanzado
May 23, 2013
from Business Wire Spanish
Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
May 23, 2013
from Business Wire News Releases
Critical Alerts For Yahoo!, Celgene, Brinker International, Qlik Technologies, and Beam Released By InvestorsObserver
May 13, 2013
from PR Newswire
Strategy Behind Our Success, We Get in Early: MDLZ, YHOO, F and CELG
May 11, 2013
from Marketwired News Releases
Acceleron’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
May 10, 2013
from Business Wire News Releases
NeoStem CEO's Letter to Shareholders
May 09, 2013
from GlobeNewswire News Releases
Key to Success, How to Profit: CLF, USB, CELG and CMCSA
May 07, 2013
from Marketwired News Releases
Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis
May 06, 2013
from Business Wire News Releases
Before the Crowd, How We Found UTX, CELG, NWSA and MDLZ
May 02, 2013
from Marketwired News Releases
Perfect Trade Setups, How to Play V, ESRX, MS and CELG
April 30, 2013
from Marketwired News Releases
Celgene Corporation to Webcast at Upcoming Investor Conferences and Analyst Day
April 29, 2013
from Business Wire News Releases
Key to Success, How to Profit: JPM, SWY, JNJ and CELG
April 26, 2013
from Marketwired News Releases
Celgene Reports First Quarter 2013 Operating and Financial Results
April 25, 2013
from Business Wire News Releases
Free Research Reports on BTU, CELG, HAS and SIX Issued by the Paragon Report
April 23, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope
April 17, 2013
from PR Newswire
Perfect Trade Setups, How to Play COH, BMY, CELG and CLF
April 15, 2013
from Marketwired News Releases
The Real Story Behind NOK, UTX, CELG and BMY
April 12, 2013
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here